Valuation: OncoTherapy Science, Inc.

Market Cap 5.72B 36.01M 32.79M 30.22M 27.49M 51.57M 3.33B 54.2M 368M 146M 1.82B 135M 132M P/E 2025
-8.97x
P/E 2026 -7.57x
Enterprise Value 3.63B 22.85M 20.81M 19.17M 17.44M 32.72M 2.12B 34.39M 233M 92.75M 1.16B 85.72M 83.91M EV / Sales 2025
9.03x
EV / Sales 2026 7.39x
Free-Float
88.54%
Yield 2025 *
-
Yield 2026 -
1 day-6.67%
1 week-12.50%
Current month-22.22%
1 month-22.22%
3 months-33.33%
6 months-30.00%
Current year-30.00%
1 week 14
Extreme 14
16
1 month 14
Extreme 14
19
Current year 14
Extreme 14
34
1 year 14
Extreme 14
34
3 years 14
Extreme 14
64
5 years 14
Extreme 14
80
10 years 14
Extreme 14
315
Manager TitleAgeSince
President 65 01/07/2022
President 50 05/12/2019
Chief Tech/Sci/R&D Officer 54 01/08/2012
Director TitleAgeSince
Director/Board Member 55 01/09/2014
Director/Board Member 50 01/06/2018
Chairman 83 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-6.67%-12.50%-33.33%-46.15% 36.01M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.90%-2.34%+26.97%+153.12% 40B
Weighted average by Cap. -1.48%-1.85%+32.15%+150.88%

Financials

2025 2026
Net sales 750M 4.72M 4.3M 3.97M 3.61M 6.77M 438M 7.11M 48.26M 19.18M 239M 17.73M 17.35M 808M 5.09M 4.64M 4.27M 3.89M 7.29M 471M 7.66M 51.99M 20.67M 257M 19.1M 18.7M
Net income -815M -5.13M -4.68M -4.31M -3.92M -7.35M -475M -7.73M -52.44M -20.84M -260M -19.26M -18.86M -910M -5.73M -5.22M -4.81M -4.38M -8.21M -531M -8.63M -58.56M -23.27M -290M -21.51M -21.06M
Net Debt -833M -5.25M -4.78M -4.4M -4.01M -7.52M -486M -7.9M -53.6M -21.3M -265M -19.69M -19.27M -2.09B -13.16M -11.99M -11.04M -10.05M -18.85M -1.22B -19.81M -134M -53.43M -666M -49.38M -48.34M
Projected Income Statement - Annual - OncoTherapy Science, Inc.
Logo OncoTherapy Science, Inc.
OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.
Employees
46
Date Price Change Volume
20/11/26 JPY 14.00 -6.67% 188,831,500
19/11/26 JPY 15.00 0.00% 141,349,900
18/11/26 JPY 15.00 0.00% 103,689,600
17/11/26 JPY 15.00 0.00% 14,310,500
16/11/26 JPY 15.00 -6.25% 195,950,100
  1. Stock Market
  2. Stocks
  3. 4564 Stock